Pluristem Therapeutics (PSTI) 2.49 0.00

PLURISTEM THERAPEUTICS, Inc.
(PSTI) 2.49 0.00

Last Trade:	2.43	Day Range:	2.42 - 2.49
Trade Time:	08:05PM	52wk Range:	1.98 - 3.66
Prev. Close:	2.43	Market Cap:	108.91M
Open:	2.49	Div Yield:	0
Volume:	103352	PE:
EPS:	-0.34

The Latest On PSTI

Pluristem's CEO Letter to Shareholders 5/23/12 7:01am

Cardiac Function in Pre-Clinical Diabetic Diastolic Heart Failure Subjects Improved by Pluristem's PLX Cells 5/15/12 7:03am

From Earlier, Compassionate Use of Pluristem's PLX Cells Saves the Life of a Child After Bone Marrow Transplantation Failure 5/9/12 9:57am

Pluristem Awarded a $3.1 Million Grant by Israeli Government 4/30/12 6:35am

Pluristem Receives U.S. FDA Clearance for Phase II Clinical Trial in Intermittent Claudication 4/17/12 7:04am

Benzinga's Top Pre-Market Gainers 3/20/12 8:13am

A Peek Into The Market Before The Trading Starts 3/20/12 7:14am

Pluristem's PLX Cells Effective in Treatment of Acute Myocardial Infarction in Animal Trial 3/20/12 7:03am

A Peek Into The Market Before The Trading Starts 2/7/12 8:21am

Pluristem to Expand Research & Development of Radiation Exposure Treatment 2/7/12 7:37am

FDA Warns About Unproven Stem Cell Claims 1/8/12 8:11pm

Global Hunter Initiates Pluristem Therapeutics at Speculative Buy, $5 PT 12/9/11 8:47am

Pluristem's CEO Letter to Shareholders 5/23/12

Cardiac Function in Pre-Clinical Diabetic Diastolic Heart Failure Subjects Improved by Pluristem's PLX Cells 5/15/12

From Earlier, Compassionate Use of Pluristem's PLX Cells Saves the Life of a Child After Bone Marrow Transplantation Failure 5/9/12

Pluristem Awarded a $3.1 Million Grant by Israeli Government 4/30/12

Pluristem Receives U.S. FDA Clearance for Phase II Clinical Trial in Intermittent Claudication 4/17/12

Benzinga's Top Pre-Market Gainers 3/20/12

A Peek Into The Market Before The Trading Starts 3/20/12

Pluristem's PLX Cells Effective in Treatment of Acute Myocardial Infarction in Animal Trial 3/20/12

A Peek Into The Market Before The Trading Starts 2/7/12

Pluristem to Expand Research & Development of Radiation Exposure Treatment 2/7/12

FDA Warns About Unproven Stem Cell Claims 1/8/12

Global Hunter Initiates Pluristem Therapeutics at Speculative Buy, $5 PT 12/9/11

NASDAQ Top Movers; Kandi, YRC, Coffee Holding, Pluristem 7/12/11

Pluristem Therapeutics Eyeing Daily Highs 7/11/11

Low Priced Stocks on the Move (IO),(ELN),(QUIK),(PSTI),(FBN) 1/25/11

Low Priced Stocks on the move (ELN),(QUIK),(FBN),(PSTI),(IO) 1/25/11

Small Cap Stocks on the move:(CRDC),(WAVX),(MNI),(CXDC),(BSDM),(ONCY) more below 1/18/11

15 Low Priced Stocks to watch on the move (CRDC),(FXEN),(RDNT),MOSY) more below 1/10/11

Pluristem Pops on Cell Therapy Data (PSTI) 9/14/10

Pluristem Therapeutics Pops on EU Grant (PSTI) 8/30/10

Global Hunter Initiates Pluristem Therapeutics at Speculative Buy, $5 PT 12/9/11

Oppenheimer Maintains Outperform Rating On Pluristem Therapeutics 6/2/11

Trade PSTI
NOW!

Partner Headlines

Company News for July 12, 2011 - Corporate Summary 7/12/11

Sonus Networks, Novavax: Small-Cap Winner 3/1/11

AK Steel, Brinker: Small-Cap Winners 1/25/11

Sterling, Ener1: Small-Cap Winners 1/18/11

Pluristem Therapeutics, Compugen: Early Volume Plays 3/2/10

Press Releases

Pluristem's CEO Letter to Shareholders 5/23/12 GlobeNewswire

Cardiac Function in Pre-Clinical Diabetic Diastolic Heart Failure Subjects Improved by Pluristem's PLX Cells 5/15/12 GlobeNewswire

Compassionate Use of Pluristem's PLX Cells Saves the Life of a Child After Bone Marrow Transplantation Failure 5/9/12 GlobeNewswire

Pluristem Awarded a $3.1 Million Grant by Israeli Government 4/30/12 GlobeNewswire

Pluristem Receives U.S. FDA Clearance for Phase II Clinical Trial in Intermittent Claudication 4/17/12 GlobeNewswire

Pluristem Forms Peripheral Artery Disease Steering Committee 4/3/12 GlobeNewswire

Pluristem Therapeutics to Present at Three Conferences in April 3/26/12 GlobeNewswire

Pluristem's PLX Cells Effective in Treatment of Acute Myocardial Infarction (AMI) in Animal Trial 3/20/12 GlobeNewswire

Pluristem Begins Up Scaling Its PLX Cell Bioreactors 3/12/12 GlobeNewswire

Pluristem Therapeutics' CEO Quarterly Update 2/29/12 GlobeNewswire

Pluristem to Expand Research & Development of Radiation Exposure Treatment 2/7/12 GlobeNewswire

Performance Style Type Indicator™ - Free Trial, Increasing the Odds of High Performance in the Work Place 2/1/12 PRWeb

Get the latest PSTI stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for PLURISTEM THERAPEUTICS, Inc. stock price.

PLURISTEM THERAPEUTICS, Inc. by YCharts

Pluristem Therapeutics (PSTI) 2.49 0.00

Quotes

Analysis

Twitter

Ownership

Earnings

The Latest On PSTI

From Benzinga's Newsdesk

Benzinga's News Delivered Free

Latest from Premium

Brain Trust

Popular Channels

Tools & Features

About Benzinga

Social